Protecting Pregnant Women From Infectious Diseases
- Conditions
- PertussisInfluenza
- Interventions
- Behavioral: P3 Vaccine Promotion Package.
- Registration Number
- NCT01761799
- Lead Sponsor
- Emory University
- Brief Summary
The primary research aim of this project is to test the effectiveness of a comprehensive, evidence-based vaccine promotion package implemented in the obstetric setting on increasing the likelihood that a pregnant woman in Georgia will receive an influenza and/or pertussis vaccine.
- Detailed Description
The primary research aim of this project is to test the effectiveness of a comprehensive, evidence-based vaccine promotion package implemented in the obstetric setting on increasing the likelihood that a pregnant woman in Georgia will receive an influenza vaccine and/or Tdap vaccine before delivery. A secondary research aim assesses whether the comprehensive package improves maternal knowledge, attitudes, and beliefs regarding maternal and infant vaccination. The intervention package will include evidence-based components aimed at the practice-level, provider-level, and patient level and will be tested through a cluster-randomized trial design. The primary outcome measure is influenza vaccine receipt during pregnancy. The secondary outcomes include 1) receipt of pertussis (Tdap) vaccination during pregnancy, and 2) changes in maternal knowledge, attitudes and beliefs regarding maternal and infant vaccination. The primary hypothesis is that implementation of a comprehensive vaccine promotion package in the obstetric setting will increase the likelihood that a pregnant woman receives an influenza and/or pertussis vaccination.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 330
- Between the ages of 18 - 50
- Currently pregnant
- Unvaccinated with 2012 - 2013 seasonal influenza vaccine
- Unvaccinated with Tdap vaccine during current pregnancy
- Under 18 years of age or over 50
- Not currently pregnant
- Previous receipt of 2012 - 2013 seasonal influenza vaccine
- Previous receipt of Tdap vaccine during current pregnancy
- Does not speak English
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description P3 Vaccine Promotion Package P3 Vaccine Promotion Package. The 5 obstetric practices randomized to the intervention arm will receive and implement all components of the evidence-based P3 vaccine promotion package at the beginning of the study.
- Primary Outcome Measures
Name Time Method Receipt of influenza vaccine during pregnancy Participants will be followed for the remaining duration of their pregnancy, which will range from approximately 2 weeks to 7 months depending upon their gestation at enrollment. Our primary outcome is receipt of a 2012 - 2013 seasonal influenza vaccine during a participant's current pregnancy, before she delivers her child(ren).
- Secondary Outcome Measures
Name Time Method Receipt of Tdap vaccine during pregnancy Participants will be followed for the remaining duration of their pregnancy, which will range from approximately 2 weeks to 7 months depending upon their gestation at enrollment. A secondary outcome is receipt of a Tdap vaccine during a participant's current pregnancy, before she delivers her child(ren).
Trial Locations
- Locations (11)
Athens OBGYN
🇺🇸Athens, Georgia, United States
Women's Healthcare Associates
🇺🇸Athens, Georgia, United States
Emory Clinic A, Clifton Road Clinic
🇺🇸Atlanta, Georgia, United States
Women's Center of Athens
🇺🇸Bogart, Georgia, United States
North Pointe OB/GYN
🇺🇸Cumming, Georgia, United States
Southern Crescent Women's Health Care
🇺🇸Fayetteville, Georgia, United States
W.T. Anderson Health Center - MCCG
🇺🇸Macon, Georgia, United States
My OB/GYN
🇺🇸Riverdale, Georgia, United States
New Millennium OB/GYN
🇺🇸Riverdale, Georgia, United States
Statesboro OB/GYN Specialists
🇺🇸Statesboro, Georgia, United States
Shaw Center for Women's Health
🇺🇸Thomasville, Georgia, United States